Cantor Fitzgerald Predicts Weaker Earnings for Zura Bio

Zura Bio Limited (NASDAQ:ZURA - Free Report) - Stock analysts at Cantor Fitzgerald reduced their FY2025 earnings estimates for Zura Bio in a research report issued on Wednesday, March 26th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company will post earnings per share of ($0.45) for the year, down from their previous forecast of ($0.40). Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for Zura Bio's current full-year earnings is ($0.65) per share.

Zura Bio (NASDAQ:ZURA - Get Free Report) last announced its quarterly earnings results on Tuesday, March 25th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.17) by $0.09. The business had revenue of $0.00 million for the quarter.

ZURA has been the topic of a number of other research reports. HC Wainwright reaffirmed a "neutral" rating and issued a $5.00 price objective on shares of Zura Bio in a research note on Tuesday, December 24th. Guggenheim reaffirmed a "buy" rating and issued a $15.00 price target on shares of Zura Bio in a report on Wednesday, March 26th. Oppenheimer restated an "outperform" rating and set a $19.00 price objective (down from $20.00) on shares of Zura Bio in a research report on Wednesday, March 26th. Finally, Chardan Capital dropped their price objective on shares of Zura Bio from $12.00 to $10.00 and set a "buy" rating for the company in a research note on Wednesday, March 26th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Zura Bio has a consensus rating of "Buy" and a consensus target price of $15.00.

Zura Bio Stock Down 8.1 %

NASDAQ:ZURA traded down $0.11 on Friday, reaching $1.19. 850,486 shares of the company's stock traded hands, compared to its average volume of 379,537. The stock has a 50-day simple moving average of $1.44 and a 200-day simple moving average of $2.69. Zura Bio has a 12 month low of $1.07 and a 12 month high of $6.35. The firm has a market cap of $77.37 million, a PE ratio of -2.24 and a beta of 0.06.

Hedge Funds Weigh In On Zura Bio

A number of large investors have recently bought and sold shares of ZURA. Charles Schwab Investment Management Inc. boosted its stake in Zura Bio by 51.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 291,807 shares of the company's stock valued at $1,185,000 after acquiring an additional 98,972 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new position in Zura Bio during the 3rd quarter valued at about $71,000. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in Zura Bio in the third quarter valued at about $46,000. MetLife Investment Management LLC purchased a new stake in Zura Bio in the third quarter valued at about $111,000. Finally, Braidwell LP acquired a new stake in Zura Bio in the third quarter worth about $10,040,000. Institutional investors own 61.14% of the company's stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.